Show simple item record

dc.contributor.authorQuintela Fandino, Miguel Angel 
dc.contributor.authorApala, Juan V
dc.contributor.authorMalon, Diego
dc.contributor.authorMouron, Silvana Andrea 
dc.contributor.authorHornedo, Javier
dc.contributor.authorGonzalez-Cortijo, Lucia
dc.contributor.authorColomer, Ramon
dc.contributor.authorGuerra, Juan
dc.date.accessioned2019-06-27T09:12:34Z
dc.date.available2019-06-27T09:12:34Z
dc.date.issued2019-05-24
dc.identifier.citationBreast Cancer Res. 2019 ;21(1):69.es_ES
dc.identifier.issn1465-542Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7806
dc.description.abstractBACKGROUND: The combined use of a FGFR1 blocker and aromatase inhibitors is appealing for treating breast cancer patients with FGFR1 amplification. However, no pharmacodynamic studies have addressed the effects of this combined target modulation. We conducted a phase 0/I clinical trial in an adjuvant setting, with the goal of obtaining pharmacodynamic proof of the effects of combined aromatase and FGFR1 inhibition and to establish the RP2D for nintedanib combined with letrozole. PATIENTS AND METHODS: Women with early-stage luminal breast cancer were eligible for enrollment in the study. Dose level 1 was nintedanib (150 mg/bid) plus letrozole (2.5 mg/day) administered for a single 28-day cycle (DLT assessment period), followed by a classic 3 + 3 schedule. FGF23 and 17-B-estradiol levels were determined on days 0 and 15; pharmacokinetic parameters were assessed on days 1 and 28. Patients were allowed to continue treatment for 6 cycles. The primary study endpoint was a demonstration of FGFR1 modulation (defined as a 25% increase in the plasma FGF23 level). RESULTS: A total of 19 patients were enrolled in the study (10 in the expansion cohort following dose escalation). At the RP2D (nintedanib 200 mg/bid plus letrozole 2.5 mg/day), we observed a 55% mean increase in the plasma FGF23 level, and 81.2% of the patients had no detectable level of 17-B-estradiol in their plasma (87.5% of the patients treated with letrozole alone). Nintedanib and letrozole displayed a pharmacokinetic interaction that led to three- and twofold increases in their respective plasma concentrations. Most G3 toxic events (5 out of 6: 2 diarrhea and 3 hypertransaminasemia) occurred subsequent to the DLT assessment period. CONCLUSION: Combined treatment with nintedanib (200 mg/bid) plus letrozole (2.5 mg/day) effectively suppressed FGFR1 and aromatase activity, and these respective doses can be used as starting doses in any subsequent trials. However, drug-drug interactions may produce tolerability issues when these drugs are co-administered for an extended time period (e.g., 6 months). Patients enrolled in future trials with these drugs should be carefully monitored for their FGF23 levels and signs of toxicity, and those findings should guide individualized treatment decisions. TRIAL REGISTRATION: This trial was registered at www.clinicaltrials.gov under reg. # NCT02619162, on December 2, 2015.es_ES
dc.description.sponsorshipMQF is a recipient of the following grants: AES - PI16/00354 funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF) and B2017/BMD3733 - Call for Coordinated Research Groups from Madrid Region - Madrid Regional Government - ERDF funds. RC is a recipient of the following grants: AES PI17/01865 and PIE15/00068 by the ISCIII and co-funded by the European Regional Development Fund (ERDF). This study was partially funded by Boehringer-Ingelheim. CRIS Contra el Cancer Foundation contributed with a generous donation to this study.es_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectFGF23es_ES
dc.subjectFGFR1es_ES
dc.subjectLetrozolees_ES
dc.subjectNintedanibes_ES
dc.subjectPharmacodynamicses_ES
dc.subjectPhase 0 clinical triales_ES
dc.subjectPhase I clinical triales_ES
dc.titleNintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibitiones_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID31126332es_ES
dc.format.volume21es_ES
dc.format.number1es_ES
dc.format.page69es_ES
dc.identifier.doi10.1186/s13058-019-1152-xes_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)
dc.contributor.funderComunidad de Madrid 
dc.contributor.funderBoehringer-Ingelheim
dc.description.peerreviewedes_ES
dc.identifier.e-issn1465-542Xes_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s13058-019-1152-x.es_ES
dc.identifier.journalBreast cancer research : BCRes_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Investigación Clínica de Cáncer de Mamaes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/AES - PI16/00354es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/AES PI17/01865es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PIE15/00068es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional